tiprankstipranks
SNY Earnings: Sanofi Jumps on Healthy Q1 Performance
Market News

SNY Earnings: Sanofi Jumps on Healthy Q1 Performance

Story Highlights

Sanofi delivered robust results for the first quarter on the back of higher Dupixent sales.

Sanofi (NASDAQ:SNY) shares jumped by over 5% in the early trading session today after the French healthcare major delivered a healthy performance for the first quarter.

Don't Miss our Black Friday Offers:

SNY’s Q1 Numbers

During the quarter, Sanofi’s top line increased by 6.7% year-over-year to €10.46 billion, with EPS for the quarter standing at €1.78. The surge in SNY’s top line was propelled by higher Dupixent sales, which rose by 24.9% to €2.83 billion. The company is on track to garner €13 billion in Dupixent sales for the full year.

Additionally, revenue from Pharma product launches skyrocketed by 90.5% to €606 million, driven by the robust performances of Nexviazyme and Altuviio. Furthermore, Consumer Healthcare (CHC) revenue increased by 9%.

However, a 2.9% increase in selling, general, and administrative expenses (SG&A), coupled with 11.8% higher research and development (R&D) expenses, contributed to a 7.4% decline in the company’s bottom line.

Sanofi’s Future Trajectory

For the full year, Sanofi expects a low-single-digit decline in its EPS due to higher tax rates. Additionally, the company foresees a negative impact of 5.5% to 6.5% on its EPS from foreign currency exchange rate fluctuations.

Simultaneously, Sanofi is relying on its late-stage development pipeline to drive growth. It anticipates 12 Phase 3 data readouts over 2024-2025. Moreover, the regulatory decision for Dupixent in COPD (Chronic Obstructive Pulmonary Disease) on June 27 is a key event to monitor. If approved, Dupixent could become the first biologic treatment for COPD, addressing a progressive disease with limited treatment options.

Is SNY Stock a Good Buy?

Today’s price surge comes after a nearly 16% drop in Sanofi’s share price over the past year. Overall, the Street has a Moderate Buy consensus rating on the stock, alongside an average SNY price target of $63. However, analysts’ views on Sanofi stock could see a revision following today’s earnings report.

Read full Disclosure

Related Articles
William WhiteSanofi (SNY) Is Seeking to Change How It Gives Discounts to Hospitals
TheFlySanofi planning changes to 340B hospital drug discount plan, WSJ reports
TipRanks Auto-Generated NewsdeskSanofi’s Sarclisa Nears EU Approval for Myeloma
Go Ad-Free with Our App